Advertisement

Journal of Urban Health

, Volume 89, Issue 1, pp 108–116 | Cite as

Prevalence and Correlates of HCV, HVB, and HIV Infection among Prison Inmates and Staff, Hungary

  • Bálint Tresó
  • Erzsébet Barcsay
  • Anna Tarján
  • Gergely Horváth
  • Ágnes Dencs
  • Andrea Hettmann
  • Mária Magdolna Csépai
  • Zoltán Győri
  • Erzsébet Rusvai
  • Mária Takács
Article

Abstract

The aim of this national, multicenter, cross-sectional study was to assess the prevalence of hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency viruses (HIV) among prisoners, and to identify related risk behaviors including injection drug use. Overall, 4,894 inmates from 20 prisons were enrolled. To have a comparison group, prison staff were also asked to take part. Altogether, 1,553 of the 4,894 inmates from seven prisons completed a questionnaire on risk behaviors. According to the survey, 1.5%, 4.9%, and 0.04% of the prisoners were tested positive for HBsAg, anti-HCV and anti-HIV, respectively. These prevalence data are among the lowest reported from prisons worldwide, although comparable to the Central European data. The prevalence of HBV, HCV, and HIV in the Hungarian prison staff was low (0.38%, 0.47%, and 0%, respectively). The rate of HCV infection was significantly higher among inmates who have ever injected drugs (22.5%) than among inmates who reported they had never injected drugs (1.1%). This first prevalence study of illegal drug injection-related viral infections among Hungarian prisoners points out that ever injecting drugs is the main reason for HCV infection among inmates. The opportunity to reach drug users infected with HCV for treatment underlines the importance of screening programs for blood-borne viruses in prisons.

Keywords

Screening HCV HBV HIV Prisoners Staff Risk factors 

Notes

Acknowledgments

This work was supported by Schering-Plough Hungary Ltd. (anti-HCV), the Hungarian Prison Service HQ, the Office of the Chief Medical Officer, and the National Center for Epidemiology (HBsAg and anti-HIV). The authors thank the staff of the Department of Hepatitis Viruses and Molecular Virology for the excellent technical assistance. We are grateful to Prof. Eva Gonczol and Carolyn Otterness for critical reading of the manuscript.

References

  1. 1.
    Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet. 1981;2:1129-1133.PubMedCrossRefGoogle Scholar
  2. 2.
    Castello G, Scala S, Palmieri G, Curley SA, Izzo F. HCV-related hepatocellular carcinoma: from chronic inflammation to cancer. Clin Immunol. 2010;134:237-250.PubMedCrossRefGoogle Scholar
  3. 3.
    Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52.PubMedCrossRefGoogle Scholar
  4. 4.
    MacDonald M, Crofts N, Kaldor J. Transmission of hepatitis C virus: rates, routes, and cofactors. Epidemiol Rev. 1996;18:137-148.PubMedGoogle Scholar
  5. 5.
    Holmberg SD. Molecular epidemiology of health care-associated transmission of hepatitis B and C viruses. Clin Liver Dis. 2010;14:37-48.PubMedCrossRefGoogle Scholar
  6. 6.
    Rauch A, Rickenbach M, Weber R, et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis. 2005;41:395-402.PubMedCrossRefGoogle Scholar
  7. 7.
    Dencs A, Farkas A, Gyugos M, et al. Phylogenetic analysis of a nosocomial transmission of hepatitis B virus at a paediatric haematology ward. Acta Microbiol Immunol Hung. 2011;58:23-29.PubMedCrossRefGoogle Scholar
  8. 8.
    EMCDDA (2010) Annual report on the state of the drugs problem in Europe. EMCDDA, Lisbon, November 2010. http://www.emcdda.europa.eu/publications/annual-report/2010. Accessed 3 May 2011.
  9. 9.
    Sweeting M, De Angelis D, Ades A, Hickman M. Estimating the prevalence of ex-injecting drug use in the population. Stat Methods Med Res. 2009;18:381-395.PubMedCrossRefGoogle Scholar
  10. 10.
    Bozsonyi K, Csesztregi T, Dudás M, et al. National Report to the EMCDDA by the Reitox National Focal Point. 2010. http://www.drogfokuszpont.hu/dfp_docs/?id=nr_10_en.pdf. Accessed 3 May 2011.
  11. 11.
    EuroHIV. HIV/AIDS Surveillance in Europe: Mid-year report 2007. Saint-Maurice, France: Institut de Veille Sanitaire; 2007. No. 76. http://www.ecdc.europa.eu/en/activities/surveillance/hiv/Documents/report_eurohiv_midyear_2007.pdf. Accessed 5 May 2011.
  12. 12.
    Kolari B, Stajduhar D, Gajnik D, Rukavina T, Wiessing L. Seroprevalence of blood-borne infections and population sizes estimates in a population of injecting drug users in Croatia. Cent Eur J Public Health. 2010;18:104-109.Google Scholar
  13. 13.
    Zabransky T, Mravcik V, Korcisova B, Rehak V. Hepatitis C virus infection among injecting drug users in the Czech Republic—prevalence and associated factors. Eur Addict Res. 2006;12:151-160.PubMedCrossRefGoogle Scholar
  14. 14.
    Laskus T, Radkowski M, Lupa E, et al. Prevalence of markers of hepatotropic viruses among drug addicts in Warsaw, Poland. J Hepatol. 1992;15:114-117.PubMedCrossRefGoogle Scholar
  15. 15.
    Cserszegi T, Csohán Á, Elekes Zs, et al. National Report to the EMCDDA by the Reitox National Focal Point. 2009. http://www.drogfokuszpont.hu/dfp_docs/?id=nr_09_en.pdf. Accessed 5 May 2011.
  16. 16.
    Allwright S, Bradley F, Long J, Barry J, Thornton L, Parry JV. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross-sectional survey. BMJ. 2000;321:78-82.PubMedCrossRefGoogle Scholar
  17. 17.
    Stark K, Bienzle U, Vonk R, Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. Int J Epidemiol. 1997;26:1359-1366.PubMedCrossRefGoogle Scholar
  18. 18.
    Hellard ME, Aitken CK, Hocking JS. Tattooing in prisons—not such a pretty picture. Am J Infect Control. 2007;35:477-480.PubMedCrossRefGoogle Scholar
  19. 19.
    Long J, Allwright S, Barry J, et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: a national cross-sectional survey. BMJ. 2001;323:1209-1213.PubMedCrossRefGoogle Scholar
  20. 20.
    Horne JA, Clements AJ, Drennan P, Stein K, Cramp ME. Screening for hepatitis C virus in the Dartmoor prison population: an observational study. J Public Health (Oxf). 2004;26:372-375.CrossRefGoogle Scholar
  21. 21.
    Hennessey KA, Kim AA, Griffin V, Collins NT, Weinbaum CM, Sabin K. Prevalence of infection with hepatitis B and C viruses and co-infection with HIV in three jails: a case for viral hepatitis prevention in jails in the United States. J Urban Health. 2009;86:93-105.PubMedCrossRefGoogle Scholar
  22. 22.
    Massad E, Rozman M, Azevedo RS, et al. Seroprevalence of HIV, HCV and syphilis in Brazilian prisoners: preponderance of parenteral transmission. Eur J Epidemiol. 1999;15:439-445.PubMedCrossRefGoogle Scholar
  23. 23.
    Weild AR, Gill ON, Bennett D, Livingstone SJ, Parry JV, Curran L. Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey. Commun Dis Public Health. 2000;3:121-126.PubMedGoogle Scholar
  24. 24.
    Babudieri S, Longo B, Sarmati L, et al. Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy. J Med Virol. 2005;76:311-317.PubMedCrossRefGoogle Scholar
  25. 25.
    Meyer MF, Wedemeyer H, Monazahian M, Dreesman J, Manns MP, Lehmann M. Prevalence of hepatitis C in a German prison for young men in relation to country of birth. Epidemiol Infect. 2007;135:274-280.PubMedCrossRefGoogle Scholar
  26. 26.
    Mahfoud Z, Kassak K, Kreidieh K, Shamra S, Ramia S. Prevalence of antibodies to human immunodeficiency virus (HIV), hepatitis B and hepatitis C and risk factors in prisoners in Lebanon. J Infect Dev Ctries. 2010;4:144-149.PubMedGoogle Scholar
  27. 27.
    Burek V, Horvat J, Butorac K, Mikulic R. Viral hepatitis B, C and HIV infection in Croatian prisons. Epidemiol Infect. 2010;138:1610-1620.PubMedCrossRefGoogle Scholar
  28. 28.
    Staneková D, Ondrejka D, Habeková M, Wimmerová S, Kucerková S. Pilot study of risk behaviour, voluntary HIV counselling and HIV antibody testing from saliva among inmates of prisons in Slovakia. Cent Eur J Public Health. 2001;9:87-90.PubMedGoogle Scholar
  29. 29.
    Caban J, Dolezal M, Błach A, Wiśniowski Z. Detection of HIV antibodies among prisoners from penitentiary units within the district penal institutions in Cracow. Przegl Epidemiol. 1990;44:155-159.PubMedGoogle Scholar
  30. 30.
    Khan N, Aswad S, Shidban H, et al. Improved detection of HCV Infection in hemodialysis patients using a new HCV RNA qualitative assay: experience of a transplant center. J Clin Virol. 2004;30:175-182.PubMedCrossRefGoogle Scholar
  31. 31.
    Wiessing L, Klempova D, Taylor C et al (2006) Protocol for the implementation of the EMCDDA key indicator: drug-related infectious diseases (DRID), draft version 6 October 2006, Project CT.04.P1.337 EMCDDA, Lisbon. http://www.emcdda.europa.eu/html.cfm/index65537EN.html. Accessed 5 March 2010.
  32. 32.
    Macalino GE, Vlahov D, Sanford-Colby S, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons [Erratum in: Am J Public Health. 2004;94:1847]. Am J Public Health. 2004;94:1218-1223.PubMedCrossRefGoogle Scholar
  33. 33.
    Kazi AM, Shah SA, Jenkins CA, Shepherd BE, Vermund SH. Risk factors and prevalence of tuberculosis, human immunodeficiency virus, syphilis, hepatitis B virus, and hepatitis C virus among prisoners in Pakistan. Int J Infect Dis. 2010;14:e60-e66.PubMedCrossRefGoogle Scholar
  34. 34.
    Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health. 2002;92:1789-1794.PubMedCrossRefGoogle Scholar
  35. 35.
    Christensen PB, Krarup HB, Niesters HG, Norder H, Georgsen J. Prevalence and incidence of bloodborne viral infections among Danish prisoners. Eur J Epidemiol. 2000;16:1043-1049.PubMedCrossRefGoogle Scholar
  36. 36.
    Adjei AA, Armah HB, Gbagbo F, et al. Correlates of HIV, HBV, HCV and syphilis infections among prison inmates and officers in Ghana: a national multicenter study. BMC Infect Dis. 2008;8:33.PubMedCrossRefGoogle Scholar
  37. 37.
    Saiz de la Hoya P, Bedia M, Murcia J, Cebria J, Sanchez-Paya J, Portilla J. Predictive markers of HIV and HCV infection and co-infection among inmates in a Spanish prison. Enferm Infecc Microbiol Clin. 2005;23:53-57.PubMedCrossRefGoogle Scholar
  38. 38.
    Hammett TM. HIV/AIDS and other infectious diseases among correctional inmates: transmission, burden, and an appropriate response. Am J Public Health. 2006;96:974-978.PubMedCrossRefGoogle Scholar
  39. 39.
    Adjei AA, Armah HB, Gbagbo F, et al. Prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus and syphilis among prison inmates and officers at Nsawam and Accra, Ghana. J Med Microbiol. 2006;55:593-597.PubMedCrossRefGoogle Scholar
  40. 40.
    Chiaramonte M, Trivello R, Renzulli G, et al. Hepatitis B virus infection in prisons. A seroepidemiological survey in prisoners and attending staff. J Hyg (Lond). 1982;89:53-58.CrossRefGoogle Scholar
  41. 41.
    Szomor KN, Dencs A, Garai E, Rusvai E, Berencsi G, Takacs M. Mutation spectra of the surface-protein-coding region of the HBV genome in HBV-vaccinated and non-vaccinated individuals in Hungary. Arch Virol. 2008;153:1885-1892.PubMedCrossRefGoogle Scholar
  42. 42.
    Solomon L, Flynn C, Muck K, Vertefeuille J. Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. J Urban Health. 2004;81:25-37.PubMedCrossRefGoogle Scholar
  43. 43.
    Kheirandish P, SeyedAlinaghi S, Jahani M, et al. Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health. 2009;86:902-908.PubMedCrossRefGoogle Scholar

Copyright information

© The New York Academy of Medicine 2011

Authors and Affiliations

  • Bálint Tresó
    • 1
  • Erzsébet Barcsay
    • 1
  • Anna Tarján
    • 1
  • Gergely Horváth
    • 1
  • Ágnes Dencs
    • 1
  • Andrea Hettmann
    • 1
  • Mária Magdolna Csépai
    • 1
  • Zoltán Győri
    • 1
  • Erzsébet Rusvai
    • 1
  • Mária Takács
    • 1
    • 2
  1. 1.National Center for EpidemiologyBudapestHungary
  2. 2.Division of VirologyNational Center for EpidemiologyBudapestHungary

Personalised recommendations